Key Advances News Today

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 21, 2023--

Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.

Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.

26.05.2023 - Positive high-level results from the DUO-E Phase III trial showed IMFINZI (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a ...